Literature DB >> 32707176

The early gut microbiome could protect against severe retinopathy of prematurity.

Dimitra Skondra1, Sarah Hilkert Rodriguez2, Anukriti Sharma3, Jack Gilbert3, Bree Andrews4, Erika C Claud5.   

Abstract

In this study, 6 infants with type 1 retinopathy of prematurity (ROP) were compared with 4 high-risk preterm neonates without any ROP but similar baseline neonatal comorbidities. The infants with type-1 ROP showed significant enrichment of Enterobacteriaceae at 28 weeks' postmenstrual age. Several metabolic pathways, including several amino acid metabolism pathways, were enriched in gut microbiota of infants without ROP. Based on these findings, we posit a possible association between early gut microbiome profile and ROP pathogenesis. Furthermore, it is possible that absence of Enterobacteriaceae overabundance, in addition to enrichment of amino acid biosynthesis pathways, may protect against severe ROP in high-risk preterm infants.
Copyright © 2020 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32707176      PMCID: PMC7680397          DOI: 10.1016/j.jaapos.2020.03.010

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  6 in total

1.  Glucose and amino acids interact with hormones to control expression of insulin-like growth factor-I and growth hormone receptor mRNA in cultured pig hepatocytes.

Authors:  J M Brameld; R S Gilmour; P J Buttery
Journal:  J Nutr       Date:  1999-07       Impact factor: 4.798

Review 2.  The microbiome and ophthalmic disease.

Authors:  Adam D Baim; Asadolah Movahedan; Asim V Farooq; Dimitra Skondra
Journal:  Exp Biol Med (Maywood)       Date:  2018-11-21

Review 3.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

4.  Association of the Intestinal Microbiome with the Development of Neovascular Age-Related Macular Degeneration.

Authors:  Martin S Zinkernagel; Denise C Zysset-Burri; Irene Keller; Lieselotte E Berger; Alexander B Leichtle; Carlo R Largiadèr; Georg M Fiedler; Sebastian Wolf
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

5.  Up-regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering Escherichia coli.

Authors:  Gaëlle Cane; Vanessa Liévin-Le Moal; Gilles Pagès; Alain L Servin; Paul Hofman; Valérie Vouret-Craviari
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

6.  Effects of Intestinal Microbiota on Brain Development in Humanized Gnotobiotic Mice.

Authors:  Jing Lu; Lei Lu; Yueyue Yu; Joanne Cluette-Brown; Camilia R Martin; Erika C Claud
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

  6 in total
  4 in total

1.  Altered Fecal Microbiome and Metabolome in a Mouse Model of Choroidal Neovascularization.

Authors:  Yun Li; Yuting Cai; Qian Huang; Wei Tan; Bingyan Li; Haixiang Zhou; Zicong Wang; Jingling Zou; Chun Ding; Bing Jiang; Shigeo Yoshida; Yedi Zhou
Journal:  Front Microbiol       Date:  2021-08-26       Impact factor: 5.640

Review 2.  Novel Potential Biomarkers for Retinopathy of Prematurity.

Authors:  Wei Tan; Bingyan Li; Zicong Wang; Jingling Zou; Yang Jia; Shigeo Yoshida; Yedi Zhou
Journal:  Front Med (Lausanne)       Date:  2022-02-02

3.  The bacterial gut microbiome of probiotic-treated very-preterm infants: changes from admission to discharge.

Authors:  Jacob A F Westaway; Roger Huerlimann; Yoga Kandasamy; Catherine M Miller; Robert Norton; Kyran M Staunton; David Watson; Donna Rudd
Journal:  Pediatr Res       Date:  2021-10-07       Impact factor: 3.953

Review 4.  A Review of the Role of the Intestinal Microbiota in Age-Related Macular Degeneration.

Authors:  Phoebe Lin; Scott M McClintic; Urooba Nadeem; Dimitra Skondra
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.